Iambic, an AI‑driven drug discovery company, raised over $100 million in an oversubscribed financing round led by institutional and strategic investors including ARK and Illumina Ventures. The company said proceeds will accelerate clinical programs and platform scaling for AI‑discovered therapeutics. The round attracted broad support from traditional life‑science investors and tech‑focused funds, signaling continued confidence in computational discovery platforms that claim to compress timelines from target to clinic. Iambic plans to use funds across IND‑enabling studies and to expand its AI‑enabled design capabilities. The financing underscores sustained capital availability for AI biotech that can show de‑risked preclinical assets and early clinical validation.